Abstract：Objective To evaluated the efficacy of biomarker-guided concurrent chemoradiotherapy in unrescetable esophageal squamous cell carcinoma patients. Methods 54 cases of unrescetable esophageal squamous cell carcinoma were enrolled in the prospective non-randomized clinical study and divided into study group and control group. All cases were treated with concurrent chemoraditherapy. Intensity-modulated radiation therapy was used with a dose of 60-66 Gy. Chemotherapy was perfromed on day 1 and d29.In the study group the selection of the chemotherapy drug was based on the excision repair cross-complementation 1(ERCC1),thymidylate synthetase (TYMS),ribonucleotide reductase M1(RRM1),and the β-tubulin isotype Ⅲ(TUBB3) mRNA expression levels. In the control group,the regiment for chemotherapy was Cisplatin plus Fluorouracil. TheObjective response rate and overall survival (OS) were calculated using Kaplan-meier method and log-rank test was used for between-group comparison. The survival rate was calculated using Kaplan-Meier method and analyzed using log-rank method,other comparison was performed by χ2 test. Results The follow-up rate was 100% in the study group and 96% in the controll group. The Objective response rate of the study group and the control group were 85% and 86(P=0.483),respectively. The median survival time (MST) in the study group was 35.5 months and that in the control group was 25.8 months. The 1-,2-,and 3-year OS rates of the study group and the control group were 84%,68%,46% and 71%,59%,28% respectively (P=0.047).No significant differences were observed in the incidence of side-effects in the two groups. Conclusions Selecting the chemotherapy drug according to biomarker,combined with radiation therapy,could improve survival.in unrescetable esophageal squamous cell carcinoma. The value needs further investigation.
Yang Zhe,Dai Honghai,Feng Alei et al. Prospective non-randomized clinical study of biomarker-guided concurrent chemoradiotherapy for unrescetable esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 807-812.
[1] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01)[J].JAMA,1999,281(17):1623-1627.DOI:10.1001/jama.281.17.1623 [2] Kato K,Muro K,Minashi K,et al. Phase Ⅱ study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage Ⅱ–Ⅲ esophageal squamous cell carcinoma:JCOG trial (JCOG 9906)[J].Int J Radiat Oncol Biol Phys,2011,81(3):684-690.DOI:10.1016/j.ijrobp.2010.06.033 [3] Suh YG,Lee IJ,Koom WS,et al. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages Ⅱ–Ⅲ esophageal cancer[J].Japan J Clin Oncol,2014,44(6):534-540.DOI:10.1093/jjco/hyu047 [4] Minsky BD,Pajak TF,Ginsberg RJ,et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J].J Clin Oncol,2002,20(5):1167-1174.DOI:10.1200/JCO.20.5.1167 [5] 王澜,王军,韩春,等.食管癌同期放化疗的价值研究[J].中华放射肿瘤学杂志,2011,20(4):291-295.DOI:10.3760/cma.j.issn.1004-4221.2011.04.009 Wang L,Wang J,Han CH,et al. The value of concurrent radiotherapy and chemotherapy for esophageal cancer[J].Chin J Radiat Oncol,2011,20(4):291-295.DOI:10.3760/cma.j.issn.1004-4221.2011.04.009 [6] 张汀荣,赵韬,徐昕,等.多西紫杉醇联合顺铂同期放疗治疗局部晚期食管癌的疗效及其不良反应[J].中华肿瘤杂志,2010,32(10):791-794.DOI:10.3760/cma.j.issn.0253-3766.2010.10.018 Zhang DR,Zhao T,Xu X,et al. The efficacy and toxicity of docetaxel combined with cisplatin combined with concurrent radiotherapy for locally advanced esophageal cancer[J].2010,32(10):791-794.DOI:10.3760/cma.j.issn.0253-3766.2010.10.018 [7] Kelsey CR,Chino JP,Willett CG,et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer[J].Int J Radiat Oncol Biol Phys,2007,69(3):770-776.DOI:http://dx.doi.org/10.1016/j.ijrobp.2007.03.035 [8] Sun Q,Liu C,Zhong H,et al. Multi-center phase Ⅱ trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer[J].Japan J Clin Oncol,2009,39(4):237-243.DOI:10.1093/jjco/hyp008 [9] 李巧巧,胡永红,刘孟忠,等.放疗同期多西紫杉醇和顺铂化疗不能手术食管癌的疗效观察[J].中华放射肿瘤学杂志,2009,18(5):379-382.DOI:10.3760/cma.j.issn.1004-4221.2009.05.379 Li QQ,Hu YH,Liu MZH,et al. To observe the curative effect of radiotherapy with concurrent docetaxel and cisplatin chemotherapy for unresectable esophageal carcinoma[J].Chin J Radiat Oncol,2009,18(5):379-382.DOI:10.3760/cma.j.issn.1004-4221.2009.05.379 [10] 王军,于金明,景绍武,等.食管鳞癌同期放化疗荟萃分析[J].中华放射肿瘤学杂志,2013,22(6):446-449.DOI:10.3760/cma.j.issn.1004-4221.2013.06.007 Wang J,Yu JM,Jing SHW,et al. Meta analysis of concurrent radiotherapy and chemotherapy for esophageal squamous cell carcinoma[J].Chin J Radiat Oncol,2013,22(6):446-449.DOI:10.3760/cma.j.issn.1004-4221.2013.06.007 [11] Olaussen KA,Dunant A,Fouret P,et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,355(10):983-991.DOI:10.1056/NEJMoa060570 [12] Chiu TJ,Chen CH,Chien CY,et al. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area[J].J Transl Med,2011,9:31.DOI:10.1186/1479-5876-9-31 [13] 拜周兰,马建萍,何剑利,等.宫颈鳞癌中 ERCC1 甲基化与顺铂为基础同期放化疗敏感性关系研究[J].中华放射肿瘤学杂志,2015,24(5):525-8.DOI:10.3760/cma.j.issn.1004-4221.2015.05.012 Bai ZHL,Ma JP,He JL,et al. Study on the relationship between ERCC1 methylation and cisplatin based concurrent radiotherapy and chemotherapy in cervical squamous cell carcinoma[J].Chin J Radiat Oncol,2015,24(5):525-8.DOI:10.3760/cma.j.issn.1004-4221.2015.05.012 [14] Wang Y,Chen J,Li X,et al. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma[J].Oncol Report,2011,25(4):1047-1052.DOI:10.3892/or.2011.1170 [15] Yasumatsu R,Nakashima T,Uryu H,et al. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil,cell proliferation and clinical outcome in head and neck squamous cell carcinoma[J].Chemotherapy,2009,55(1):36-41.DOI:10.1159/000175465 [16] Afzal S,Gusella M,Jensen SA,et al. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer[J].Pharmacogenomics,2011,12(9):1257-1267.DOI:10.2217/pgs.11.83 [17] Watson RG,Muhale F,Thorne LB,et al. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy[J].Eur J Cancer,2010,46(18):3358-3364.DOI:10.1016/j.ejca.2010.07.011 [18] Bepler G,Kusmartseva I,Sharma S,et al. RM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4731-4737.DOI:10.1200/JCO.2006.06.1101 [19] Lee JJ,Maeng CH,Baek SK,et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1(RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)[J].Lung Cancer,2010,70(2):205-210.DOI:10.1016/j.lungcan.2010.02.005 [20] Gong W,Zhang X,Wu J,et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer:a meta-analysis[J].Lung Cancer,2012,75(3):374-380.DOI:10.1016/j.lungcan.2011.08.003 [21] Sève P,Dumontet C.Is class Ⅲ beta-tubulin a predictive factor in patients receiving tubulin-binding agents?[J]. Lancet Oncol,2008,9(2):168-175.DOI:10.1016/S1470-2045(08)70029-9 [22] Yu J,Gao J,Lu Z,et al. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine[J].Med Oncol,2012,29(5):3029-3034.DOI:10.1007/s12032-012-0292-y [23] Zhang HL,Ruan L,Zheng LM,et al. Association between class Ⅲβ-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer:a meta-analysis[J].Lung Cancer,2012,77(1):9-15.DOI:10.1016/j.lungcan.2012.01.005 [24] Bepler G,Williams C,Schell MJ,et al. Randomized international phase ⅲ trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer[J].J Clin Oncol,2013,31(19)2404-2412.DOI:10.1200/jco.2012.46.9783 [25] 袁芃,缪小平,张雪梅,等.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-3.DOI:10.3321/j.issn:1000-467X.2005.12.019 Yuan F,Miu XP,Zhang XM,et al. Nucleotide excision repair system gene polymorphism and the relationship between platinum drug sensitivity in patients with advanced non small cell lung cancer[J].Chin Oncol,2005,24(12):1510-3.DOI:10.3321/j.issn:1000-467X.2005.12.019 [26] 张萌,刘巍,王淑琴.ERCC1 基因在食管癌中的研究进展[J].中国肿瘤,2009,18(3):018 Zhang M,Liu W,Wang SHQ.Research progress of ERCC1 gene in esophageal cancer[J].Tumor China,2009,18(3):018 [27] 高志强,韩宝惠,沈策,等.ERCC1 蛋白检测指导晚期非小细胞肺癌个体化治疗的临床研究[J].中国癌症杂志,2013,23(5):328-33.DOI:10.3969/j.issn.1007-3969.2013.05.002 Gao ZHQ,Han BH,SHen C,et al. Detection of ERCC1 protein in advanced non small cell lung cancer:a clinical study[J].Chin J Cancer,2013,23(5):328-33.DOI:10.3969/j.issn.1007-3969.2013.05.002
2016, Vol. 25 
